PDCD1 and follicular lymphoma: Westin et al. hypothesized that the lack of immune-related adverse events could be attributed to the low-frequency dosage of pidilizumab compared to that of other PD-1 blocking antibodies, B-cell depletion by rituximab, and the immunocompromised state of patients with follicular lymphoma.